Codex DNA Receivables

Codex DNA (DNAY) currently reports a receivables of $1.3M as of September 2024. That compares with $5.4M in the prior-year period — down 76.4% year over year. Use the charts on this page to explore Codex DNA's receivables history and peer comparisons.

Codex DNA's receivables decreased from $5.4M to $1.3M — a 76.4% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Codex DNA reported $1.3M in receivables as of September 2024. That compares with $5.4M in the prior-year period — down 76.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Codex DNA, and consider following DNAY for alerts when major investors trade the stock.

Codex DNA is classified in the Healthcare sector. On receivables, it currently shows $1.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNAY with unrelated industries.